Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘A Game Changer:’ Cures 2.0 Would Provide $11bn In ‘Subscription’ Contracts For New Antibiotics

Executive Summary

The PASTEUR Act would delink some of an antibiotic’s revenue from prescription sales, with the goal of revitalizing the antibiotic pipeline with additional private investment while encouraging good public health stewardship of critically needed medicines.

You may also be interested in...



ARPA-H: New Health Research Agency Faces Old Concerns About Disrupting Private Investment

Proposed Advanced Research Project Agency for Health also needs to distinguish itself from NCATS, which faced many of the same questions when it was created a decade ago. Disagreements also persist about whether ARPA-H should be housed in NIH or HHS.

Cidara’s Rezafungin Hits Approvable Endpoints For Candida Infections

Phase III data for the novel echinocandin demonstrated non-inferiority to caspofungin for all-cause mortality at day 30 and for global cure at day 14. Regulatory filings are planned for 2022.

US PASTEUR Act Promises More Than Other National AMR Initiatives

PASTEUR Act in the US is the most promising initiative out there to address antimicrobial resistance.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel